Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa AdCD40L Immunogene Therapy for Patients With Advanced Malignant Disease.

NCT01455259 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.

NCT NCT01455259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa AdCD40L Immunogene Therapy for Patients With Advanced Malignant Disease.
Lead sponsor
Uppsala University
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2011
Completion date
January 31, 2016
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma